[SCHEDULE 13G] Trevi Therapeutics, Inc. Passive Investment Disclosure (>5%)
FMR LLC reports 5.1% stake in Trevi Therapeutics
Trevi Therapeutics reported that investment manager FMR LLC, together with Abigail P. Johnson, has filed a Schedule 13G showing beneficial ownership of 6,500,009.33 shares of Trevi common stock, representing 5.1% of the class as of 12/31/2025.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Trevi Therapeutics reported that investment manager FMR LLC, together with Abigail P. Johnson, has filed a Schedule 13G showing beneficial ownership of 6,500,009.33 shares of Trevi common stock, representing 5.1% of the class as of 12/31/2025.
FMR LLC has sole voting power over 6,485,775 shares and sole dispositive power over the full 6,500,009.33 shares, with no shared voting or dispositive power. The securities were acquired and are held in the ordinary course of business, and not with the purpose or effect of changing or influencing control of Trevi.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Trevi Therapeutics (TRVI) did FMR LLC report?
FMR LLC reported beneficial ownership of 6,500,009.33 shares of Trevi Therapeutics common stock, representing 5.1% of the outstanding class as of December 31, 2025. This makes FMR a significant institutional shareholder in the company.
Who are the reporting persons in the Trevi Therapeutics (TRVI) Schedule 13G?
The Schedule 13G identifies FMR LLC and Abigail P. Johnson as reporting persons. FMR LLC is the institutional manager holding and voting the shares, while Johnson is listed as a control person with sole dispositive power over the same 6,500,009.33 shares.
What voting and dispositive powers does FMR LLC have over Trevi (TRVI) shares?
FMR LLC has sole voting power over 6,485,775 Trevi Therapeutics shares and sole dispositive power over 6,500,009.33 shares. It reports no shared voting or shared dispositive power, indicating centralized decision-making authority over these holdings.
Did FMR LLC acquire Trevi Therapeutics (TRVI) shares to influence control?
The filing states the Trevi Therapeutics shares were acquired and are held in the ordinary course of business. It specifically certifies they were not acquired, and are not held, for the purpose or effect of changing or influencing control of the issuer.
Do other investors have rights to income from Trevi Therapeutics (TRVI) shares held by FMR?
The Schedule 13G notes one or more other persons may have rights to receive dividends or sale proceeds from Trevi shares held by FMR-related entities. However, no single such person has an interest exceeding five percent of Trevi’s total outstanding common stock.
What is the relevant date for FMR LLC’s Trevi Therapeutics (TRVI) ownership?
The date of the event triggering the Schedule 13G filing is December 31, 2025. The 6,500,009.33 shares and 5.1% ownership percentage for Trevi Therapeutics common stock are reported as of that date, providing a specific ownership snapshot.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
TREVI THERAPEUTICS INC
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
89532M101
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
89532M101
1
Names of Reporting Persons
FMR LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
6,485,775.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
6,500,009.33
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,500,009.33
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
CUSIP No.
89532M101
1
Names of Reporting Persons
Abigail P. Johnson
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
6,500,009.33
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,500,009.33
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.1 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
TREVI THERAPEUTICS INC
(b)
Address of issuer's principal executive offices:
195 CHURCH STREET,16TH FLOOR,NEW HAVEN,CT,USA,06510
Item 2.
(a)
Name of person filing:
FMR LLC
(b)
Address or principal business office or, if none, residence:
245 Summer Street, Boston, Massachusetts 02210
(c)
Citizenship:
Not applicable
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP No.:
89532M101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
6500009.33
(b)
Percent of class:
5.1 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Please see the responses to Items 5 and 6 on the cover page.
(ii) Shared power to vote or to direct the vote:
0.00
(iii) Sole power to dispose or to direct the disposition of:
6500009.33
(iv) Shared power to dispose or to direct the disposition of:
0.00
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of TREVI THERAPEUTICS INC. No one other person's interest in the COMMON STOCK of TREVI THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See attached Exhibit 99.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
FMR LLC
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:
02/04/2026
Abigail P. Johnson
Signature:
Stephanie J. Brown
Name/Title:
Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:
02/04/2026
Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
